Staphylokinase for massive pulmonary embolism with shock
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a single injection of a clot-busting drug called staphylokinase for people with a massive pulmonary embolism that is causing shock or very low blood pressure. It aims to see how well the drug works in this emergency situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed massive pulmonary embolism (a large blood clot in the lung) seen on a CT scan.
- You must have signs that the right side of your heart is struggling (like low blood pressure or shock).
- Your symptoms must have started within the last 14 days.
- You must not have any condition that raises your risk of dangerous bleeding (such as recent surgery, stomach ulcers, or blood thinners).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a catheter (a thin tube) to remove blood clots from the lungs early can help people with a severe, life-threatening pulmonary embolism. It is for patients who are in shock or have had a cardiac arrest due to a large clot.
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
This trial studies using a medication called non-immunogenic staphylokinase as part of standard clot-busting treatment for an acute ischemic stroke. It may help clinicians improve blood flow after the stroke using an approach designed to be less likely to trigger immune reactions.
This trial tests whether adding a low dose of a clot-busting medicine to the standard emergency procedure to open blocked heart arteries can improve outcomes for people having a heart attack. It aims to see if the combination is safe and more effective than the standard procedure alone.
This trial tests whether a standard procedure using a catheter to deliver clot-dissolving medicine directly into the lung artery works well for people with a serious but not immediately life-threatening blood clot in the lungs (pulmonary embolism). It aims to improve heart function and reduce long-term complications.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
Hear when a new Pulmonary Embolism Acute Massive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.